Pfizer Inc. (PFE) - Get Report shares were slightly higher in morning trading Thursday after the company announced positive results from its late stage trials of prostate cancer treatment candidate Xtandi. 

The trial was conducted in conjunction with Astellas Pharma Inc. (ALPMF) and found that Xtandi, when combined with a standard prostate cancer therapy, improved survival rates relative to just standard prostate treatments on its own. 

There are currently no FDA-approved treatments for patients with non-metastatic castration-resistant prostate cancer. 

More of What's Trending on TheStreet: